CJC-1295 with DAC vs CJC-1295 without DAC (Modified GRF 1-29)
"CJC-1295" is used loosely in the peptide space to refer to two related but pharmacologically distinct molecules. CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog covalently linked via a maleimidopropionic acid spacer to serum albumin, giving it a multi-day half-life. CJC-1295 without DAC — which is more accurately called Modified GRF 1-29 or Mod GRF 1-29 — is the same 29-amino-acid sequence without the albumin-binding linker, clearing in about 30 minutes. They are often marketed under the same "CJC-1295" name and sold on adjacent shelves, but they produce fundamentally different GH exposure patterns and are used differently in clinical and biohacking protocols.
Both are sold as "CJC-1295" but they're not the same drug. The DAC version has a linker that binds albumin, stretching the half-life from 30 minutes to 6–8 days — one weekly injection, sustained GH exposure. The no-DAC version (Modified GRF 1-29) clears in 30 minutes, produces discrete pulses, and needs daily dosing. DAC wins on convenience, no-DAC wins on physiologic pulse patterning and cleaner side effects. Vendors often don't label this clearly — always confirm which one you're buying.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
CJC-1295 (no DAC)
A modified growth hormone releasing hormone analog with a shorter half-life than DAC-conjugated CJC-1295, allowing more physiological GH pulsing.
| Category | CJC-1295 | CJC-1295 (no DAC) |
|---|---|---|
| Molecular Structure | Modified GRF 1-29 (29 amino acids with 4 substitutions for stability) covalently linked to a maleimidopropionic acid (MPA) spacer that binds serum albumin via cysteine-34 | Modified GRF 1-29 (29 amino acids with 4 substitutions: D-Ala²-Gln⁸-Ala¹⁵-Leu²⁷) — the same peptide as CJC-DAC without the albumin-binding linker |
| More Precise Name | CJC-1295 (ConjuChem's original designation; 'with DAC' clarifies vs. the unlinked form) | Modified GRF 1-29 / Mod GRF 1-29 / CJC-1295 (no DAC) — often confusingly marketed under the same 'CJC-1295' umbrella |
| Half-Life | ~6–8 days (sustained albumin-bound circulation) | ~30 minutes (cleared rapidly via enzymatic degradation and renal clearance) |
| GH Release Pattern | Sustained, relatively flat GHRH-receptor stimulation — 'GH bleed' pattern with elevated baseline and blunted pulses | Discrete GH pulses following each injection — preserves the physiologic pulsatile pattern that mirrors endogenous GHRH |
| IGF-1 Response | Larger sustained IGF-1 elevation due to continuous receptor stimulation — some clinicians view this as the primary reason to choose DAC, others as the primary concern | More modest IGF-1 rise following each pulse, typically closer to high-physiologic range than supraphysiologic |
| Dosing Frequency | 1–2× per week (typically 2mg per injection for 2×/week protocols, or a single weekly dose) | 1–3× per day (typically 100 mcg per injection, timed before bed and/or post-workout to align with natural GH pulses) |
| Typical Stacking Partner | Ipamorelin daily before bed (the CJC-DAC supplies sustained GHRH signal, Ipamorelin adds pulsatile ghrelin-receptor triggers) | Ipamorelin at the same injection site and timing (Mod GRF 1-29 + Ipamorelin stacked before bed is a classic pulsatile biohacking protocol) |
| Physiology Philosophy | Non-physiologic — GH secretion in healthy adults is strongly pulsatile, and sustained GHRH stimulation departs from that pattern. Advocates argue the IGF-1 elevation matters more than pulse architecture; skeptics argue receptor desensitization and loss-of-feedback are real concerns. | Physiologic — preserves the endogenous GH pulse rhythm, which is hypothesized to be important for downstream IGF-1 signaling, sleep-wake coupling of GH, and avoiding receptor desensitization. |
| Onset of Measurable Effect | 1–2 weeks to see IGF-1 rise on labs; body composition / recovery effects typically 6–12 weeks | IGF-1 response detectable within days of consistent dosing; body composition / recovery effects on the same 6–12 week timeline |
| Common Side Effects | Water retention and facial puffiness (more pronounced than no-DAC), numbness/tingling in extremities, lethargy, injection site reactions — generally proportional to the sustained exposure | Injection site flushing or tingling, transient mild water retention, occasional pre-bed warmth/sleepiness — generally better tolerated than DAC at typical doses |
| Convenience | High — a single weekly injection covers the full week | Lower — requires daily (sometimes multiple-times-daily) injections, usually timed to sleep or training |
| Clinical Monitoring | IGF-1 trending; higher ceiling and less predictable interpretation due to non-pulsatile exposure — one argument against DAC is that IGF-1 can drift into supraphysiologic range on typical protocols | IGF-1 trending with more straightforward physiologic interpretation; fasting glucose and HbA1c as with any GH-axis intervention |
| FDA Status | Not FDA-approved. Historically available through 503A compounding pharmacies; the FDA's 2023 review narrowed that access pathway. ConjuChem's original development program reached Phase II and was not completed. | Not FDA-approved. Historically available through 503A compounding pharmacies, similarly constrained by the 2023 FDA review. Mod GRF 1-29 is often the more accessible of the two in current compounded-peptide channels. |
| WADA Status | Prohibited at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Detection assays have been validated and athletes have been sanctioned for CJC-1295 use. | Prohibited at all times under S2. Shorter half-life does not materially change detection-window risk at typical use frequencies. |
| Cost (Compounded, Monthly) | ~$100–250 depending on dose and pharmacy | ~$80–200; often the cheaper per-month option when used without CJC-DAC |
| Best Candidate Profile | Users prioritizing convenience of less-frequent dosing and willing to accept a non-pulsatile exposure pattern; tolerating more water-retention side effects in exchange for sustained IGF-1 elevation | Users prioritizing physiologic GH pulse architecture, lower side-effect burden, and tighter control over timing — commonly paired with Ipamorelin for the best-tolerated daily injectable GH-secretagogue protocol |
In depth
The core question: sustained or pulsatile?
The peptides are nearly identical in sequence — the difference is a single covalent modification, the Drug Affinity Complex (DAC). DAC is a linker that binds serum albumin in circulation, which drags the peptide's half-life from about 30 minutes (no DAC) to 6–8 days (with DAC). That single modification cascades into everything downstream: dosing frequency, GH release pattern, IGF-1 response, side effect profile, and a meaningful philosophical divide about whether sustained or pulsatile GHRH stimulation is the better approach. This is the entire debate. Everything else in this comparison flows from that one structural difference.
CJC-1295 with DAC: the convenience option
A once- or twice-weekly injection of CJC-DAC produces sustained GHRH-receptor activation that elevates IGF-1 to a higher and flatter level than any pulsatile protocol can achieve. For users who prioritize simplicity and want measurable IGF-1 rise on minimal injection burden, the DAC version is the logical choice. Convenience is a real clinical variable — people who only need to inject weekly sustain therapy longer than people injecting daily. The trade-offs are real. Water retention and facial puffiness are more prominent with DAC (proportional to the sustained exposure). The non-pulsatile pattern departs from endogenous GH physiology, and the long-term consequences of that departure aren't well characterized. Some clinicians argue that sustained GHRH receptor stimulation risks downregulation and loss-of-feedback effects that pulsatile dosing avoids — this is a theoretical concern, not a demonstrated outcome, but it's why thoughtful clinicians often prefer the no-DAC version when patients don't specifically need the weekly-dosing convenience.
CJC-1295 without DAC (Mod GRF 1-29): the pulsatile option
The no-DAC version is more accurately called Modified GRF 1-29, but most vendors market it as "CJC-1295" anyway, which is where the naming confusion originates. Each 100 mcg injection produces a discrete GH pulse shaped similarly to what endogenous GHRH would generate. IGF-1 rises more modestly and predictably. Daily dosing — often paired with Ipamorelin at the same injection, so you get a GHRH-receptor pulse and a ghrelin-receptor pulse simultaneously — is the mainstream biohacking protocol for users who want GH-axis stimulation without departing from physiologic patterns. Side effects are generally milder: less water retention, less facial puffiness, more controllable dose-response. The cost is injection frequency — daily (sometimes twice daily) subcutaneous injections versus weekly.
The naming confusion is a real problem
Many compounded-peptide vendors sell both DAC and no-DAC as "CJC-1295" without clearly distinguishing them on the label or product listing. This has caused users to unknowingly switch pharmacology when they change vendors, which is a meaningful clinical event — the GH patterns, dosing schedules, and side effect profiles are materially different. If you're buying "CJC-1295," specifically confirm whether it's the DAC-conjugated or the no-DAC (Modified GRF 1-29) form. If the vendor can't tell you, that's itself a signal about their quality control — and a reason to look elsewhere.
Regulatory and WADA status
Neither form is FDA-approved for any indication. ConjuChem's original development program for DAC-conjugated CJC-1295 reached Phase II and was abandoned. Both peptides sit in the compounded-peptide gray zone that the FDA's 2023 review has narrowed — access through 503A pharmacies has become tighter, though the no-DAC version remains more readily available in current compounded channels. Both are prohibited under WADA S2 at all times, and detection assays exist for both; competitive athletes should avoid both forms entirely.
Bottom line
Pick DAC if you value convenience and are comfortable with sustained (rather than pulsatile) GH exposure. Pick no-DAC / Modified GRF 1-29 if you value physiologic pulse patterning and the cleaner side-effect profile, and can commit to daily dosing. The mainstream injectable biohacking protocol — no-DAC CJC-1295 + Ipamorelin before bed — uses the no-DAC version for exactly this reason. Either way, confirm which form you're actually buying, use under clinician supervision with IGF-1 and fasting glucose monitoring, and remember that GH peptides amplify whatever sleep, resistance training, and nutrition you're already doing — they don't substitute for those inputs.
These peptides are often used together. See our stack profiles for combination details.